A very interesting study by Sabari et al. retrospectively investigated the effectiveness of immune checkpoints inhibitors in MET exon 14-mutated NSCLC patients, and showed that, despite them expressing high PD-L1 levels, treatment responses were very rare, with very short durations of response and progression-free survival, and they were also lower than those observed with MET-targeted therapy [78]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.